Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life

Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life

Robert S Epstein,1 Upal K Basu Roy,2 Matti Aapro,3 Tehseen Salimi,4 Donald Moran,4 JoAnn Krenitsky,1 Megan L Leone-Perkins,5 Cynthia Girman,6 Courtney Schlusser,7 Jeffrey Crawford8 1Epstein Health, LLC., Woodcliff Lake, NJ, USA; 2LUNGevity Foundation, Bethesda, MD, USA; 3Clinique De Genolier, Genoli...

Full description

Bibliographic Details
Main Authors:	Epstein RS, Basu Roy UK, Aapro M, Salimi T, Moran D, Krenitsky J, Leone-Perkins ML, Girman C, Schlusser C, Crawford J
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-02-01
Series:	Patient Preference and Adherence
Subjects:	cancer chemotherapy myelosuppression real world quality of life patient burden
Online Access:	https://www.dovepress.com/cancer-patientsrsquo-perspectives-and-experiences-of-chemotherapy-indu-peer-reviewed-article-PPA

Similar Items

Promotion of myelopoiesis in myelosuppressed mice by Ganoderma lucidum polysaccharides
by: Xiao Ling Zhu, et al.
Published: (2012-02-01)

H2S protects against fatal myelosuppression by promoting the generation of megakaryocytes/platelets
by: Huan-Di Liu, et al.
Published: (2016-02-01)

Alopecia as the first manifestation of azathioprine myelosuppression in a genetically predisposed patient
by: Debashish Mishra, et al.
Published: (2019-01-01)

The mechanisms of blood system regulation under myelosuppressive influences
by: E. D. Goldberg, et al.
Published: (2002-06-01)

Complications of MRSA Treatment: Linezolid-induced Myelosuppression Presenting with Pancytopenia
by: Gorchynski, Julie A, et al.
Published: (2008-08-01)

Comparison of Different Time Nutritional Intervention on Chemotherapy-induced Ⅳ Degree Myelosuppression in Cancer Patients
by: QI Xiaoguang, et al.
Published: (2018-01-01)

POLYSACCHARIDES TUSSILAGOFARFARA L. REDUCE MYELOSUPPRESSION INDUCED BY CISPLATIN AND ETOPOSIDE
by: E. A. Safonova, et al.
Published: (2017-09-01)

The Impact of the Epigenetic Cancer Drug Azacitidine on Host Immunity: The Role of Myelosuppression, Iron Overload and <i>tp53</i> Mutations in a Zebrafish Model
by: Shu-Ching Wang, et al.
Published: (2019-09-01)

Pharmacometric Models for Improved Prediction of Myelosuppression and Treatment Response in Oncology
by: Quartino, Angelica L
Published: (2011)

Wheat bran arabinoxylan supplementation alleviates 5-fluorouracil induced mucositis and myelosuppression in BALB/c mice
by: Minkyung Song, et al.
Published: (2016-03-01)

Factors Predicting Severe Myelosuppression and Its Influence on Fertility in Patients with Low-Risk Gestational Trophoblastic Neoplasia Receiving Single-Agent Methotrexate Chemotherapy
by: Tu X, et al.
Published: (2020-06-01)

Effect of Kanglaite combined with chemotherapy on myelosuppression, immune function and tumor markers levels in patients with breast cancer
by: Qi Pan, et al.
Published: (2017-09-01)

TPGS-Modified Long-Circulating Liposomes Loading Ziyuglycoside I for Enhanced Therapy of Myelosuppression
by: Song T, et al.
Published: (2021-09-01)

Zusanli (ST36) Acupoint Injection With Dexamethasone for Chemotherapy-Induced Myelosuppression: A Systematic Review and Meta-Analysis
by: Jiangfeng Chen, et al.
Published: (2021-07-01)

Ginsenoside Rg3 for Chemotherapy-Induced Myelosuppression: A Meta-Analysis and Systematic Review
by: Linlin Pan, et al.
Published: (2020-05-01)

Association Between Genetic Polymorphisms of Metabolic Enzymes and Azathioprine-Induced Myelosuppression in 1,419 Chinese Patients: A Retrospective Study
by: Zhao-Yang Chen, et al.
Published: (2021-05-01)

Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era
by: Gary H. Lyman, et al.
Published: (2021-07-01)

Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies
by: Hussein M, et al.
Published: (2021-08-01)

Transcriptome Profiling Analysis Reveals the Potential Mechanisms of Three Bioactive Ingredients of Fufang E’jiao Jiang During Chemotherapy-Induced Myelosuppression in Mice
by: Xue Li, et al.
Published: (2018-06-01)

Jian-Pi-Bu-Xue-Formula Alleviates Cyclophosphamide-Induced Myelosuppression via Up-Regulating NRF2/HO1/NQO1 Signaling
by: Qiuju Huang, et al.
Published: (2020-08-01)

The prophylactic and therapeutic effects of moxibustion combined with traditional Chinese medicine decoction for treating chemotherapy-induced myelosuppression in early-stage breast cancer: study protocol for a randomized controlled trial
by: Yajie Ji, et al.
Published: (2020-10-01)

Astragaloside IV and Saponins of Rhizoma Polygonati Cure Cyclophosphamide-Induced Myelosuppression in Lung Adenocarcinoma via Down-Regulating miR-142-3p
by: Xian Gu, et al.
Published: (2021-04-01)

Linezolid induced pancytopenia in a patient of extensively drug-resistant pulmonary tuberculosis: An unusual outcome
by: Rajiv Garg, et al.
Published: (2016-01-01)

A Case of Successful Treatment of Gram-Negative Sepsis Associated with Toxic Myelosuppression in a Patient with HIV-Associated Non-Hodgkin’s Lymphoma
by: D. D. Morikov, et al.
Published: (2021-04-01)

Severe Sunitinib-Induced Myelosuppression in a Patient with a CYP 3A4 Polymorphism
by: Patel, Nirav D., et al.
Published: (2017)

The Role of Adenosine Receptor Agonists in Regulation of Hematopoiesis
by: Michal Hofer, et al.
Published: (2011-01-01)

Modulation of Animal and Human Hematopoiesis by β-Glucans: A Review
by: Milan Pospíšil, et al.
Published: (2011-09-01)

Protective effects of Acanthopanax senticosus - Ligustrum lucidum combination on bone marrow suppression induced by chemotherapy in mice
by: Chunyun Wang, et al.
Published: (2019-01-01)

Sulfasalazine-Induced Pancytopenia in Ulcerative Colitis
by: NS Neki, et al.
Published: (2016-09-01)

Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study
by: Bernardo Leon Rapoport, et al.
Published: (2018-09-01)

A Primary Mediastinal Large B-Cell Lymphoma Patient With COVID-19 Infection After Intensive Immunochemotherapy: A Case Report
by: Qiuhui Li, et al.
Published: (2020-05-01)

Validation of Risk of Chemotherapy-Induced Neutropenia: Experience from Oncology Hospital of Nepal
by: Sapkota B, et al.
Published: (2020-05-01)

Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice
by: Derek Weycker, et al.
Published: (2019-02-01)

Myeloprotective activity of crude methanolic leaf extract of Cassia occidentalis in cyclophosphamide-induced bone marrow suppression in Wistar rats
by: Emeka E Neboh, et al.
Published: (2015-01-01)

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects
by: Karsten Roth, et al.
Published: (2019-10-01)

by: P.B. Soares, et al.
Published: (2013-01-01)

In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow
by: P.B. Soares, et al.
Published: (2013-01-01)

Stimulatory Action of Cyclooxygenase Inhibitors on Hematopoiesis: A Review
by: Lenka Weiterová, et al.
Published: (2012-05-01)

Pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects
by: Hendrik Wessels, et al.
Published: (2019-10-01)

Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis
by: Narendranath Epperla, et al.
Published: (2020-02-01)